+ Watch REGN
on My Watchlist
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
Regeneron has been on a tear the last few years with approval of Eylea for wet AMD followed by a commercial performance that far exceeded expectations. The company has made substantial progress expanding the indications for Eylea and has also achieved approval of Zaltrap for colon cancer. Phase III trials of other pipeline compounds are in progress for the superindications of RA and hypercholesterolemia.Sequential revenues were a little disappointing last quarter which likely explains why the stock is off recent highs in the 180's. But the two year chart shows periodic pullbacks in the stock that are always followed by new all-time highs. I expect that barring a bombshell development with Eylea, revenues will resume their upward trend and positive pipeline developments will drive the stock north of 200.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions